BioLineRx Ltd.
19 Hartum Street
P.O. Box 45158
Jerusalem 91450
Tel: 972-2-548-9100
Fax: 972-2-548-9101
Website: http://www.biolinerx.com/
Email: info@BioLineRx.com
422 articles about BioLineRx Ltd.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
3/4/2024
BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, "Process for Manufacturing Peptide," covering a method of manufacturing motixafortide (BL-8040) that is suitable for large scale production.
-
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
2/28/2024
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
-
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
2/16/2024
BioLineRx Ltd. announced that new post-hoc subgroup analyses and pharmacodynamic data will be presented on APHEXDA® for CD34+ hematopoietic stem cell mobilization in patients with multiple myeloma at the 2024 Tandem Meetings.
-
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
11/20/2023
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates.
-
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
11/13/2023
BioLineRx Ltd., a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open.
-
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
10/31/2023
M.S.Q. Ventures is pleased to announce that its client, BioLineRx Ltd., has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. and an associated investor for the development of motixafortide across all indications in Asia.
-
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
9/28/2023
BioLineRx Ltd. announced encouraging data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer.
-
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
9/19/2023
BioLineRx Ltd. today announced that pilot phase data from an investigator-initiated, open-label, multicenter Phase 2 clinical trial with motixafortide in first-line pancreatic ductal adenocarcinoma (PDAC) will be presented at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts, September 27-30, 2023.
-
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
9/11/2023
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA.
-
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
8/30/2023
BioLineRx Ltd. reported its unaudited financial results for the second quarter ended June 30, 2023, and provided corporate and portfolio updates.
-
In the next two weeks, the FDA will hand out regulatory verdicts to BMS, Outlook Therapeutics and BioLineRx.
-
BioLineRx to Report Second Quarter 2023 Results on August 30, 2023
8/22/2023
BioLineRx Ltd. announced today it will release its unaudited financial results for the quarter ended June 30, 2023 on Wednesday, August 30, 2023, before the U.S. markets open.
-
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide
7/17/2023
BioLineRx Ltd. today announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase.
-
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
5/24/2023
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its unaudited financial results for the first quarter ended March 31, 2023, and provided corporate and portfolio updates.
-
BioLineRx to Report First Quarter 2023 Results on May 24, 2023
5/17/2023
BioLineRx Ltd. announced today that it will release its unaudited financial results for the quarter ended March 31, 2023 on Wednesday, May 24, 2023, before the U.S. markets open.
-
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
4/25/2023
BioLineRx Ltd. today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.
-
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
4/17/2023
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced the publication of data from the Company's GENESIS Phase 3 clinical trial in the peer-reviewed journal Nature Medicine.
-
BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
3/22/2023
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its audited 2022 annual financial results for the year ended December 31, 2022, and provided recent corporate and portfolio updates.
-
BioLineRx to Report 2022 Annual Financial Results on March 22, 2023
3/15/2023
BioLineRx Ltd. announced today that it will release its audited financial results for the year ended December 31, 2022 on Wednesday, March 22, 2023, before the U.S. market closes.